Gastrointestinal Lymphoma

위장관 림프종

  • Kim, Sang-Gyun (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine)
  • 김상균 (서울대학교 의과대학 내과학교실, 간연구소)
  • Received : 2010.05.31
  • Accepted : 2010.07.14
  • Published : 2010.07.30

Abstract

Gastrointestinal lymphoma is the leading cause of extranodal lymphoma. Gastric lymphoma is very common in patients with gastrointestinal lymphoma, and diffuse large B-cell lymphoma and marginal zone B-cell lymphoma of the mucosaassociated lymphoid tissue (MALT) are the most common histological types. Helicobacter pylori (H. pylori) has been implicated in the pathogenesis of MALT lymphoma, and eradication of H. pylori has successfully resulted in the remission of MALT lymphoma. In the cases of H. pylori-negative MALT lymphoma or advanced gastric lymphoma, radiation therapy and/or chemotherapy can be used to treat the disease and achieve remission.

위장관 림프종은 림프절 외 림프종 중 가장 흔한 호발 부위 중의 하나이며, 그 중 위에 발생하는 경우가 가장 흔하다. 조직학적으로는 미만성 거대 B세포 림프종과 점막연관성 림프종이 가장 흔한 형태이고, 이 중 점막연관성 림프종은 헬리코박터 파일로리 감염과 관련이 있다는 것이 밝혀지면서 낮은 병기인 경우 제균 치료 만으로도 완치에 이를 수 있다는 것이 알려져 왔다. 제균 치료 이후 완전 관해에 걸리는 기간은 평균 6개월 이내이며, 제균 치료 이후 완전 관해에 이르기까지 3개월 간격으로 추적관찰을 통해 관해 여부를 확인한다. 관해에 이른 경우 6개월 및 1년마다 추적 검사를 시행해볼 수 있으며, 완전관해에 이르지 않거나 헬리코박터 파일로리 음성으로 제균 치료가 불가능한 경우에는 방사선 치료 또는 항암치료를 통하여 장기를 보존할 수 있으며 장기 생존율을 기대할 수 있다.

Keywords

References

  1. d'Amore F, Christensen BE, Brincker H, et al. Clinicopathological features and prognostic factors in extranodal non Hodgkin's lymphomas. Danish LYFO Study Group. Eur J Cancer 1991;27:1201-1208. https://doi.org/10.1016/0277-5379(91)90081-N
  2. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Hematol 2006;136:521-538.
  3. Isaacson PG. The MALT lymphoma concept updated. Ann Oncol 1995;6:319-320. https://doi.org/10.1093/oxfordjournals.annonc.a059177
  4. Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphoma of MALT type develop along 2 distinct pathways. Blood 2002;99:3-9. https://doi.org/10.1182/blood.V99.1.3
  5. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000;96:410-419.
  6. Caletti G, Ferrari A, Brocchi E, Barbara L. Accuracy of endoscopic ultrasonography in the diagnosis and staging of gastric cancer and lymphoma. Surgery 1993;113:14-27.
  7. Nakamura S, Matsuomoto T, Suekane H, et al. Predictive value of endoscopic ultrasonography for remission of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 2001;48:454-460. https://doi.org/10.1136/gut.48.4.454
  8. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997;89:1350-1355. https://doi.org/10.1093/jnci/89.18.1350
  9. Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacter pylori eradication therapy in stage IE high-grade mucosaassociated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001;19:4245-4251. https://doi.org/10.1200/JCO.2001.19.22.4245
  10. Raderer M, Streubel B, Wohrer S, Hafner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006;55: 616-618. https://doi.org/10.1136/gut.2005.083022
  11. Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-8024. https://doi.org/10.1200/JCO.2005.02.3903
  12. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34-37. https://doi.org/10.1136/gut.53.1.34